Anemia associated with pregnancy is a worldwide public health problem . A recent WHO report estimates the anemia prevalence among pregnant women to be 55.9% globally. Iron Deficiency Anemia (IDA) is the most common form of anemia in women of reproductive age, and it affects approximately 15% of the world’s population. When it occurs during pregnancy, anemia has a significant impact on the health of the fetus as well as that of the mother.
The treatment of IDA is directed at replenishing hemoglobin and compensating for the deficit in stored iron by supplying sufficient iron. The Iron Polysaccharide Complex (IPC) has been formulated in such a way that the elemental form is in a nonionic state. This ensures that there is no gastric irritation with iron polysaccharide complex. In addition, the high elemental iron content of IPC eliminates the need for frequent dosing and therefore improves compliance.